By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Zafgen 

29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: 617-236-0535 Fax: 617-249-0490


SEARCH JOBS



Segment
Start Up





Company News
Zafgen (ZFGN) Announces Closing Of Public Offering Of Common Stock And Full-Exercise Of Option To Purchase Additional Shares 1/29/2015 7:43:45 AM
Zafgen (ZFGN) Announces Pricing Of Public Offering Of Common Stock 1/23/2015 7:23:40 AM
Zafgen (ZFGN) Announces Proposed Public Offering Of Common Stock 1/21/2015 7:29:40 AM
Zafgen (ZFGN) Announces Positive Results From Phase 2 Clinical Trial Of Beloranib In Hypothalamic Injury Associated Obesity 1/7/2015 7:19:52 AM
Zafgen (ZFGN) Added To NASDAQ Biotechnology Index 12/16/2014 8:00:17 AM
Zafgen (ZFGN) Announces Initiation Of Phase 2b Trial Of Beloranib In Severe Obesity 12/15/2014 7:20:55 AM
Zafgen (ZFGN) Reports Third Quarter 2014 Financial Results 11/12/2014 7:52:51 AM
Zafgen (ZFGN) To Host Conference Call To Discuss Third Quarter 2014 Financial Results 11/4/2014 9:54:12 AM
Zafgen (ZFGN) To Ring The Nasdaq Stock Market Closing Bell 10/24/2014 10:23:20 AM
Zafgen (ZFGN) Announces Initiation Of Phase 3 Trial Of Beloranib In Prader-Willi Syndrome 10/1/2014 7:53:38 AM
123456
//-->